NO853241L - Farmasoeytiske antitumorpreparater og fremgngsmaate for fremstilling av disse - Google Patents
Farmasoeytiske antitumorpreparater og fremgngsmaate for fremstilling av disseInfo
- Publication number
- NO853241L NO853241L NO853241A NO853241A NO853241L NO 853241 L NO853241 L NO 853241L NO 853241 A NO853241 A NO 853241A NO 853241 A NO853241 A NO 853241A NO 853241 L NO853241 L NO 853241L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- compounds
- hydrogen
- cell
- cdm
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 6
- 230000008929 regeneration Effects 0.000 claims abstract description 6
- 238000011069 regeneration method Methods 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 2
- 125000005645 linoleyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 78
- 238000010790 dilution Methods 0.000 description 38
- 239000012895 dilution Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 16
- 241000700605 Viruses Species 0.000 description 13
- 230000032823 cell division Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003632 microfilament Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000030944 contact inhibition Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 230000010262 intracellular communication Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 230000005741 malignant process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- MUCUYUJZKDAUMX-UHFFFAOYSA-N N-[2-[2-[2-(octadeca-9,11-dienoylamino)ethylamino]ethylamino]ethyl]octadeca-9,11-dienamide Chemical compound C(CNCCNC(CCCCCCCC=CC=CCCCCCC)=O)NCCNC(CCCCCCCC=CC=CCCCCCC)=O MUCUYUJZKDAUMX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- VASZKKUIFVKZER-UHFFFAOYSA-N n-[2-(2-heptadec-8-enyl-4,5-dihydroimidazol-1-yl)ethyl]octadec-9-enamide Chemical class CCCCCCCCC=CCCCCCCCC(=O)NCCN1CCN=C1CCCCCCCC=CCCCCCCCC VASZKKUIFVKZER-UHFFFAOYSA-N 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU834348A HU200093B (en) | 1983-12-20 | 1983-12-20 | Process for production of medical compositions against tumour |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO853241L true NO853241L (no) | 1985-08-16 |
Family
ID=10967718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO853241A NO853241L (no) | 1983-12-20 | 1985-08-16 | Farmasoeytiske antitumorpreparater og fremgngsmaate for fremstilling av disse |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5068240A (fr) |
| EP (1) | EP0165960B1 (fr) |
| JP (1) | JPS61500729A (fr) |
| KR (1) | KR850700108A (fr) |
| AU (1) | AU574754B2 (fr) |
| BR (1) | BR8407235A (fr) |
| CA (1) | CA1255231A (fr) |
| DE (1) | DE3477881D1 (fr) |
| DK (1) | DK168530B1 (fr) |
| EG (1) | EG17013A (fr) |
| ES (1) | ES8604490A1 (fr) |
| FI (1) | FI853199A0 (fr) |
| GR (1) | GR82477B (fr) |
| HU (1) | HU200093B (fr) |
| IL (1) | IL73825A0 (fr) |
| IN (1) | IN160438B (fr) |
| IT (1) | IT1177485B (fr) |
| MA (1) | MA20305A1 (fr) |
| NO (1) | NO853241L (fr) |
| NZ (1) | NZ210558A (fr) |
| PT (1) | PT79698B (fr) |
| WO (1) | WO1985002769A1 (fr) |
| ZA (1) | ZA849897B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6646149B1 (en) | 1997-07-15 | 2003-11-11 | Nicolaas M. J. Vermeulin | Polyamine analogues as therapeutic and diagnostic agents |
| US7208528B1 (en) | 1997-07-15 | 2007-04-24 | Mediquest Therapeutics, Inc. | Polyamine analogues as therapeutic and diagnostic agents |
| AU758570B2 (en) * | 1997-07-15 | 2003-03-27 | Mediquest Therapeutics, Inc. | Novel polyamine analogues as therapeutic and diagnostic agents |
| USRE43327E1 (en) | 2001-01-08 | 2012-04-24 | Aminex Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
| GB0425556D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Novel compounds |
| HUP0900271A2 (hu) * | 2009-04-30 | 2010-11-29 | Adam Kovacs | Levegõszûrõ betét védõmaszkhoz, illetve légkezelõ berendezésekhez széles hatásspektrumú gyógyászati kezelési és prevenciós eljárásokban történõ alkalmazásra |
| JP5836394B2 (ja) * | 2010-12-30 | 2015-12-24 | サムヤン バイオファーマシューティカルズ コーポレイション | 陽イオン性脂質を含む陰イオン性薬物伝達体およびその製造方法 |
| RU2487122C1 (ru) * | 2012-05-24 | 2013-07-10 | Общество с ограниченной ответственностью Научно-производственное объединение "НИИПАВ" | Способ получения алкилимидазолина |
| KR102454783B1 (ko) | 2016-03-25 | 2022-10-13 | 아미넥스 테라퓨틱스, 인크. | 생체이용가능한 폴리아민 |
| JP2023545674A (ja) | 2020-09-30 | 2023-10-31 | アミネックス セラピューティクス， インコーポレイテッド | ポリアミン輸送阻害剤およびｄｆｍｏの配合原薬 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3085940A (en) * | 1960-05-09 | 1963-04-16 | American Cyanamid Co | Nu, nu'-methylene-bis-amides for the suppression of tumors |
| FR1202M (fr) * | 1960-05-09 | 1962-03-26 | American Cyanamid Co | Compositions d'amides. |
-
1983
- 1983-12-20 HU HU834348A patent/HU200093B/hu not_active IP Right Cessation
-
1984
- 1984-12-14 IL IL73825A patent/IL73825A0/xx unknown
- 1984-12-14 NZ NZ210558A patent/NZ210558A/en unknown
- 1984-12-17 GR GR82477A patent/GR82477B/el unknown
- 1984-12-18 DE DE8585900164T patent/DE3477881D1/de not_active Expired
- 1984-12-18 BR BR8407235A patent/BR8407235A/pt unknown
- 1984-12-18 US US07/533,943 patent/US5068240A/en not_active Expired - Fee Related
- 1984-12-18 PT PT79698A patent/PT79698B/pt not_active IP Right Cessation
- 1984-12-18 JP JP60500050A patent/JPS61500729A/ja active Pending
- 1984-12-18 KR KR1019850700171A patent/KR850700108A/ko not_active Application Discontinuation
- 1984-12-18 WO PCT/HU1984/000062 patent/WO1985002769A1/fr active IP Right Grant
- 1984-12-18 AU AU37801/85A patent/AU574754B2/en not_active Ceased
- 1984-12-18 EP EP85900164A patent/EP0165960B1/fr not_active Expired
- 1984-12-19 MA MA20529A patent/MA20305A1/fr unknown
- 1984-12-19 ES ES538852A patent/ES8604490A1/es not_active Expired
- 1984-12-19 ZA ZA849897A patent/ZA849897B/xx unknown
- 1984-12-19 CA CA000470495A patent/CA1255231A/fr not_active Expired
- 1984-12-20 IT IT24159/84A patent/IT1177485B/it active
- 1984-12-23 EG EG804/84A patent/EG17013A/xx active
- 1984-12-27 IN IN1042/MAS/84A patent/IN160438B/en unknown
-
1985
- 1985-07-19 DK DK329985A patent/DK168530B1/da not_active IP Right Cessation
- 1985-08-16 NO NO853241A patent/NO853241L/no unknown
- 1985-08-20 FI FI853199A patent/FI853199A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IT1177485B (it) | 1987-08-26 |
| EP0165960A1 (fr) | 1986-01-02 |
| AU574754B2 (en) | 1988-07-14 |
| ES538852A0 (es) | 1986-02-01 |
| CA1255231A (fr) | 1989-06-06 |
| FI853199L (fi) | 1985-08-20 |
| NZ210558A (en) | 1988-04-29 |
| HU200093B (en) | 1990-04-28 |
| FI853199A0 (fi) | 1985-08-20 |
| IN160438B (fr) | 1987-07-11 |
| EG17013A (en) | 1993-07-30 |
| JPS61500729A (ja) | 1986-04-17 |
| PT79698B (en) | 1987-01-15 |
| KR850700108A (ko) | 1985-10-25 |
| AU3780185A (en) | 1985-07-12 |
| EP0165960B1 (fr) | 1989-04-26 |
| ES8604490A1 (es) | 1986-02-01 |
| IT8424159A0 (it) | 1984-12-20 |
| DK329985D0 (da) | 1985-07-19 |
| HUT39602A (en) | 1986-10-29 |
| DE3477881D1 (en) | 1989-06-01 |
| PT79698A (en) | 1985-01-01 |
| DK329985A (da) | 1985-07-19 |
| BR8407235A (pt) | 1985-11-26 |
| US5068240A (en) | 1991-11-26 |
| GR82477B (en) | 1985-04-11 |
| WO1985002769A1 (fr) | 1985-07-04 |
| DK168530B1 (da) | 1994-04-18 |
| ZA849897B (en) | 1985-08-28 |
| IL73825A0 (en) | 1985-03-31 |
| MA20305A1 (fr) | 1985-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Awad et al. | Comparative toxicology of trypan blue, brilliant blue G, and their combination together with polyethylene glycol on human pigment epithelial cells | |
| JPH0466453B2 (fr) | ||
| US20080076772A1 (en) | Anti-Inflammatory Agents | |
| NO853241L (no) | Farmasoeytiske antitumorpreparater og fremgngsmaate for fremstilling av disse | |
| Cobb et al. | Effect of Actinomycin D on Tissue Cul-tures of Normal and Neoplastic Cells 1, 2, 3 | |
| Richardson et al. | Action of polylysine on some ascites tumors in mice. | |
| KR920002935B1 (ko) | 맥관 형성 저해제 | |
| Morgan | Studies on the relationship of pteroylglutamic acid to the growth of psittacosis virus (strain 6BC) | |
| Lankford et al. | Some aspects of nutritional variation of the gonococcus | |
| Chu et al. | Differential characteristics of two newly established human breast carcinoma cell lines | |
| Zirvi et al. | Correlation of drug sensitivity on human colon adenocarcinoma cells grown in soft agar and in athymic mice | |
| EP0179127B1 (fr) | Leucoreguline, une lymphokine antitumorale, et ses utilisations therapeutiques | |
| JPS59222417A (ja) | Ｎ，Ｎ−ジエチル−５−メチル−２Ｈ−１−ベンゾチオピラノ−〔４，３，２−ｃｄ〕−インダゾ−ル−２−エタナミン組成物 | |
| Ohya | Studies on the effect of the tissue substance" cornin" on transplantable malignant tumors in mice | |
| JPH01117881A (ja) | 抗腫瘍性およびウイルス性アルカロイド | |
| Ozols et al. | Direct cloning of human ovarian cancer in soft agar: clinical limitations and pharmacologic applications | |
| CN111729074B (zh) | 多肽rl25在制备抗肿瘤药物中的应用 | |
| Blumenfeld et al. | A chemotactic inhibitor produced by blast cells and present in the serum of a patient with acute lymphoblastic leukemia | |
| JPH06501024A (ja) | 皮膚腫瘍形成を予防し、存在する腫瘍の後退の原因になるための医薬組成物と方法 | |
| Hug et al. | Chemosensitivities of human clonogenic breast tumor cells | |
| Burns et al. | Inhibition of marrow granulocytic colony formation by phytohemagglutinin | |
| Wierda et al. | Partial characterization of bone marrow hemopoiesis in mice after cisplatin administration | |
| Joshi et al. | Modified Combination Chemotherapy of Leukemia: An Attempt to Overcome Drug Resistance | |
| CN116942680A (zh) | 一种治疗耐药的非小细胞肺癌的药物组合物 | |
| Chaplinski et al. | Study of differentiation of fresh myeloid leukemic cells by physiologic agents that induce a human promyelocytic leukemic line (HL-60) to differentiate |